Why Australia can't win against Trump's MFN policy

Pharmas have a huge incentive to raise prices for their medicines or delay launches in countries such as Australia because of US President Donald Trump's Most Favoured Nation (MFN) policy, new modelling published in The Lancet has found.

To see the whole article please log in.

Simon Webster

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here